Log in to your Inderes Free account to see all free content on this page.
Scandion Oncology
0.168 SEK -1.18%Be the first to follow this company
Scandion Oncology is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has been used in certain standard cancer treatments during preclinical studies. The company was founded in 2017 and is headquartered in Copenhagen, Denmark.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
SCOL
Daily low / high price
0.165 / 0.173
SEK
Market cap
38.96M SEK
Turnover
189.45K SEK
Volume
1.1M
Latest videos
Financial calendar
Interim report
29.08.2024
Interim report
27.11.2024
Annual report
28.02.2025
ShowingAll content types
Scandion Oncology board member Michel Ducreux steps down, joins advisory board
SCANDION ONCOLOGY ANNOUNCES OUTCOME OF THE RIGHTS ISSUE
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Scandion announces change of Certified Adviser to Vator Securities
SCANDION ONCOLOGY PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE
Redeye: Scandion Oncology Q1 2024 - Funding for CORIST part 3 extension
SCANDION ONCOLOGY ANNOUNCES THE FINAL TERMS OF THE RIGHTS ISSUE
![Scandion Oncology, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/c06ebf17-358d-46c1-99b3-80945024eee0.png)
Scandion Oncology, Audiocast with teleconference, Q1, 2024
Scandion Oncology – Interim Report Q1 2024
Invitation to Scandion Oncology webcast and conference call May 22, 2024
Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101
Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors
Scandion Oncology to Host R&D Update May 15
Scandion Oncology – Notice convening the Annual General Meeting
SCANDION ONCOLOGY CARRIES OUT A RIGHTS ISSUE OF APPROXIMATELY SEK 60 MILLION SECURED UP TO APPROXIMATELY SEK 30.6 MILLION
Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival
Scandion Oncology - Annual Report 2023
Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial
Redeye: Scandion Oncology Q4 2023 - Striving towards randomised controlled data
![Scandion Oncology, Audiocast with teleconference, Q4, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/07127bad-fc39-49dd-8a39-998bae38ebc7.png)